StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-13 | $7.92 | $8.05 | +1.64% | 1.1M |
| 05-14 | $8.00 | $7.29 | -8.88% | 1.0M |
| 05-15 | $7.18 | $7.34 | +2.23% | 1.0M |
| 05-18 | $7.32 | $6.90 | -5.74% | 0.9M |
| 05-19 | $6.83 | $6.65 | -2.64% | 0.7M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
No sell-side coverage available for LENZ.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for LENZ.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q1 2025 2025-03-31 | Annual 2024 2024-12-31 |
|---|---|---|---|---|
Revenue | $1.90M | $19.09M | $0.00 | $0.00 |
Operating Income | $-44.13M | $-91.14M | $-16.93M | $-58.61M |
Net Income | $-41.49M | $-82.13M | $-14.62M | $-49.77M |
EPS (Diluted) | $-1.32 | $-2.85 | $-0.53 | $-2.34 |
Total Assets | $272.54M | $305.88M | $201.25M | $215.30M |
Total Liabilities | $26.04M | $21.54M | $9.24M | $11.22M |
Cash & Equivalents | $24.77M | $25.18M | $23.04M | $20.16M |
Free Cash Flow OCF − CapEx | $-33.60M | $-70.00M | $-16.16M | $-59.86M |
Shares Outstanding | 31.35M | 31.34M | 27.54M | 27.52M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.